Market closedNon-fractional
ATAI Life Sciences/ATAI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About ATAI Life Sciences
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Ticker
ATAI
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Berlin, Germany
Employees
83
Website
www.atai.life
ATAI Metrics
BasicAdvanced
$213M
Market cap
-
P/E ratio
-$0.21
EPS
0.84
Beta
-
Dividend rate
Price and volume
Market cap
$213M
Beta
0.84
Financial strength
Current ratio
7.827
Quick ratio
7.206
Long term debt to equity
9.21
Total debt to equity
9.32
Interest coverage (TTM)
-42.06%
Management effectiveness
Return on assets (TTM)
-26.02%
Return on equity (TTM)
-15.92%
Valuation
Price to revenue (TTM)
731.988
Price to book
0.95
Price to tangible book (TTM)
0.95
Price to free cash flow (TTM)
-2.364
Growth
Revenue change (TTM)
2.59%
Earnings per share change (TTM)
-77.73%
3-year revenue growth
-75.94%
3-year earnings per share growth
-51.46%
What the Analysts think about ATAI
Analyst Ratings
Majority rating from 7 analysts.
ATAI Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$27M
46.70%
Profit margin
0.00%
NaN%
ATAI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.21
$0.25
-$0.12
-$0.17
-
Expected
-$0.21
-$0.20
-$0.16
-$0.18
-$0.16
Surprise
1.23%
-224.11%
-26.53%
-6.59%
-
ATAI News
AllArticlesVideos
atai Life Sciences CEO talks successful Phase 1 trial of IV psilocin formulation – ICYMI
Proactive Investors·7 days ago
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
GlobeNewsWire·1 week ago
atai Life Sciences optimistic as IV psilocin shows promise in treating depression in early trial
Proactive Investors·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ATAI Life Sciences stock?
ATAI Life Sciences (ATAI) has a market cap of $213M as of July 06, 2024.
What is the P/E ratio for ATAI Life Sciences stock?
The price to earnings (P/E) ratio for ATAI Life Sciences (ATAI) stock is 0 as of July 06, 2024.
Does ATAI Life Sciences stock pay dividends?
No, ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next ATAI Life Sciences dividend payment date?
ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders.
What is the beta indicator for ATAI Life Sciences?
ATAI Life Sciences (ATAI) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell ATAI Life Sciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.